Multiple splicing variants of Naf1/ABIN-1 transcripts and their alterations in hematopoietic tumors

Yasuhiro Shiote, Mamoru Oouchida, Yoshimi Jitsumori, Yoichiro Ogama, Yoshinobu Matsuo, Fumihiko Ishimaru, Mitsune Tanimoto, Kenji Shimizu

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Naf1 (Nef-associated factor 1)/TNIP1/ABIN-1 (A20-binding inhibitor of NF-κB activation) is a cellular protein that interacts and cooperates with the NFκB inhibiting protein A20. It is reported that Naf1 attenuates epidermal growth factor (EGF)/extracellular-signal-regulated kinase2 (ERK2) nuclear signaling. Naf1 also binds to Nef, which plays a key role in acquired immunodeficiency syndrome pathogenesis and HIV-1 virus replication. Naf1 mRNA consists of 18 exons and multiple splice variants have been reported; two isoforms for exon 1, deletion of exon 2 and isoforms α and β for exon 18. Using specimens from 29 acute myeloid leukemia (AML) patients, we detected a high frequency of allelic loss on DNA at STS marker D5S2014 near the Naf1 gene. We therefore performed mutation and expression analyses using leukemia-lymphoma lines and 6 pairs of clinical AML samples. There was no mutation in the Naf1 coding region of any sample. As a result of expression analysis, we identified novel splice variants of the Naf1 gene; deletion of exon 16 (Naf1 α2, Naf1 β2), deletion of exon 16 with an insertion (Naf1 α3, Naf1 β3) and deletion of exons 16 and 17 (Naf1 α4). Naf1 α3 and β3 showed premature termination. In peripheral blood mononucleocytes (PBMNCs) from healthy adults, almost no expression of full-length Naf1 (Naf1FL), Naf1 α3 and β3 were observed. In contrast, their expression was clear in AML blasts and in the majority of leukemia-lymphoma lines investigated. Naf1 α2 was widely expressed in PBMNCs from healthy adults, AML blasts and cell lines, suggesting it is the main transcript of the Naf1 gene. Luciferase assay revealed that Naf1 α2 had equal NF-κB inhibitory effect to that of Naf1FL, while Naf1 α4 was less effective. In clinical AML patients, the expression of Naf1 α3 was much higher at diagnosis than on remission after chemotherapy, suggesting the possible dominant negative effect of Naf1 α3.

Original languageEnglish
Pages (from-to)917-923
Number of pages7
JournalInternational Journal of Molecular Medicine
Volume18
Issue number5
Publication statusPublished - Nov 2006

Fingerprint

Exons
Acute Myeloid Leukemia
Neoplasms
Lymphoma
Protein Isoforms
Leukemia
Genes
Mutation
Loss of Heterozygosity
Myeloid Cells
Virus Replication
Luciferases
Epidermal Growth Factor
HIV-1
Acquired Immunodeficiency Syndrome
Proteins
Drug Therapy
Cell Line
Messenger RNA
DNA

Keywords

  • Acute myeloid leukemia
  • Alternative splice variant
  • Loss of heterozygosity
  • Naf1/ABIN-1/TNIP1
  • Nuclear factor κB

ASJC Scopus subject areas

  • Genetics

Cite this

Shiote, Y., Oouchida, M., Jitsumori, Y., Ogama, Y., Matsuo, Y., Ishimaru, F., ... Shimizu, K. (2006). Multiple splicing variants of Naf1/ABIN-1 transcripts and their alterations in hematopoietic tumors. International Journal of Molecular Medicine, 18(5), 917-923.

Multiple splicing variants of Naf1/ABIN-1 transcripts and their alterations in hematopoietic tumors. / Shiote, Yasuhiro; Oouchida, Mamoru; Jitsumori, Yoshimi; Ogama, Yoichiro; Matsuo, Yoshinobu; Ishimaru, Fumihiko; Tanimoto, Mitsune; Shimizu, Kenji.

In: International Journal of Molecular Medicine, Vol. 18, No. 5, 11.2006, p. 917-923.

Research output: Contribution to journalArticle

Shiote, Y, Oouchida, M, Jitsumori, Y, Ogama, Y, Matsuo, Y, Ishimaru, F, Tanimoto, M & Shimizu, K 2006, 'Multiple splicing variants of Naf1/ABIN-1 transcripts and their alterations in hematopoietic tumors', International Journal of Molecular Medicine, vol. 18, no. 5, pp. 917-923.
Shiote, Yasuhiro ; Oouchida, Mamoru ; Jitsumori, Yoshimi ; Ogama, Yoichiro ; Matsuo, Yoshinobu ; Ishimaru, Fumihiko ; Tanimoto, Mitsune ; Shimizu, Kenji. / Multiple splicing variants of Naf1/ABIN-1 transcripts and their alterations in hematopoietic tumors. In: International Journal of Molecular Medicine. 2006 ; Vol. 18, No. 5. pp. 917-923.
@article{df869c75469949a99ec3f911541c23f0,
title = "Multiple splicing variants of Naf1/ABIN-1 transcripts and their alterations in hematopoietic tumors",
abstract = "Naf1 (Nef-associated factor 1)/TNIP1/ABIN-1 (A20-binding inhibitor of NF-κB activation) is a cellular protein that interacts and cooperates with the NFκB inhibiting protein A20. It is reported that Naf1 attenuates epidermal growth factor (EGF)/extracellular-signal-regulated kinase2 (ERK2) nuclear signaling. Naf1 also binds to Nef, which plays a key role in acquired immunodeficiency syndrome pathogenesis and HIV-1 virus replication. Naf1 mRNA consists of 18 exons and multiple splice variants have been reported; two isoforms for exon 1, deletion of exon 2 and isoforms α and β for exon 18. Using specimens from 29 acute myeloid leukemia (AML) patients, we detected a high frequency of allelic loss on DNA at STS marker D5S2014 near the Naf1 gene. We therefore performed mutation and expression analyses using leukemia-lymphoma lines and 6 pairs of clinical AML samples. There was no mutation in the Naf1 coding region of any sample. As a result of expression analysis, we identified novel splice variants of the Naf1 gene; deletion of exon 16 (Naf1 α2, Naf1 β2), deletion of exon 16 with an insertion (Naf1 α3, Naf1 β3) and deletion of exons 16 and 17 (Naf1 α4). Naf1 α3 and β3 showed premature termination. In peripheral blood mononucleocytes (PBMNCs) from healthy adults, almost no expression of full-length Naf1 (Naf1FL), Naf1 α3 and β3 were observed. In contrast, their expression was clear in AML blasts and in the majority of leukemia-lymphoma lines investigated. Naf1 α2 was widely expressed in PBMNCs from healthy adults, AML blasts and cell lines, suggesting it is the main transcript of the Naf1 gene. Luciferase assay revealed that Naf1 α2 had equal NF-κB inhibitory effect to that of Naf1FL, while Naf1 α4 was less effective. In clinical AML patients, the expression of Naf1 α3 was much higher at diagnosis than on remission after chemotherapy, suggesting the possible dominant negative effect of Naf1 α3.",
keywords = "Acute myeloid leukemia, Alternative splice variant, Loss of heterozygosity, Naf1/ABIN-1/TNIP1, Nuclear factor κB",
author = "Yasuhiro Shiote and Mamoru Oouchida and Yoshimi Jitsumori and Yoichiro Ogama and Yoshinobu Matsuo and Fumihiko Ishimaru and Mitsune Tanimoto and Kenji Shimizu",
year = "2006",
month = "11",
language = "English",
volume = "18",
pages = "917--923",
journal = "International Journal of Molecular Medicine",
issn = "1107-3756",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Multiple splicing variants of Naf1/ABIN-1 transcripts and their alterations in hematopoietic tumors

AU - Shiote, Yasuhiro

AU - Oouchida, Mamoru

AU - Jitsumori, Yoshimi

AU - Ogama, Yoichiro

AU - Matsuo, Yoshinobu

AU - Ishimaru, Fumihiko

AU - Tanimoto, Mitsune

AU - Shimizu, Kenji

PY - 2006/11

Y1 - 2006/11

N2 - Naf1 (Nef-associated factor 1)/TNIP1/ABIN-1 (A20-binding inhibitor of NF-κB activation) is a cellular protein that interacts and cooperates with the NFκB inhibiting protein A20. It is reported that Naf1 attenuates epidermal growth factor (EGF)/extracellular-signal-regulated kinase2 (ERK2) nuclear signaling. Naf1 also binds to Nef, which plays a key role in acquired immunodeficiency syndrome pathogenesis and HIV-1 virus replication. Naf1 mRNA consists of 18 exons and multiple splice variants have been reported; two isoforms for exon 1, deletion of exon 2 and isoforms α and β for exon 18. Using specimens from 29 acute myeloid leukemia (AML) patients, we detected a high frequency of allelic loss on DNA at STS marker D5S2014 near the Naf1 gene. We therefore performed mutation and expression analyses using leukemia-lymphoma lines and 6 pairs of clinical AML samples. There was no mutation in the Naf1 coding region of any sample. As a result of expression analysis, we identified novel splice variants of the Naf1 gene; deletion of exon 16 (Naf1 α2, Naf1 β2), deletion of exon 16 with an insertion (Naf1 α3, Naf1 β3) and deletion of exons 16 and 17 (Naf1 α4). Naf1 α3 and β3 showed premature termination. In peripheral blood mononucleocytes (PBMNCs) from healthy adults, almost no expression of full-length Naf1 (Naf1FL), Naf1 α3 and β3 were observed. In contrast, their expression was clear in AML blasts and in the majority of leukemia-lymphoma lines investigated. Naf1 α2 was widely expressed in PBMNCs from healthy adults, AML blasts and cell lines, suggesting it is the main transcript of the Naf1 gene. Luciferase assay revealed that Naf1 α2 had equal NF-κB inhibitory effect to that of Naf1FL, while Naf1 α4 was less effective. In clinical AML patients, the expression of Naf1 α3 was much higher at diagnosis than on remission after chemotherapy, suggesting the possible dominant negative effect of Naf1 α3.

AB - Naf1 (Nef-associated factor 1)/TNIP1/ABIN-1 (A20-binding inhibitor of NF-κB activation) is a cellular protein that interacts and cooperates with the NFκB inhibiting protein A20. It is reported that Naf1 attenuates epidermal growth factor (EGF)/extracellular-signal-regulated kinase2 (ERK2) nuclear signaling. Naf1 also binds to Nef, which plays a key role in acquired immunodeficiency syndrome pathogenesis and HIV-1 virus replication. Naf1 mRNA consists of 18 exons and multiple splice variants have been reported; two isoforms for exon 1, deletion of exon 2 and isoforms α and β for exon 18. Using specimens from 29 acute myeloid leukemia (AML) patients, we detected a high frequency of allelic loss on DNA at STS marker D5S2014 near the Naf1 gene. We therefore performed mutation and expression analyses using leukemia-lymphoma lines and 6 pairs of clinical AML samples. There was no mutation in the Naf1 coding region of any sample. As a result of expression analysis, we identified novel splice variants of the Naf1 gene; deletion of exon 16 (Naf1 α2, Naf1 β2), deletion of exon 16 with an insertion (Naf1 α3, Naf1 β3) and deletion of exons 16 and 17 (Naf1 α4). Naf1 α3 and β3 showed premature termination. In peripheral blood mononucleocytes (PBMNCs) from healthy adults, almost no expression of full-length Naf1 (Naf1FL), Naf1 α3 and β3 were observed. In contrast, their expression was clear in AML blasts and in the majority of leukemia-lymphoma lines investigated. Naf1 α2 was widely expressed in PBMNCs from healthy adults, AML blasts and cell lines, suggesting it is the main transcript of the Naf1 gene. Luciferase assay revealed that Naf1 α2 had equal NF-κB inhibitory effect to that of Naf1FL, while Naf1 α4 was less effective. In clinical AML patients, the expression of Naf1 α3 was much higher at diagnosis than on remission after chemotherapy, suggesting the possible dominant negative effect of Naf1 α3.

KW - Acute myeloid leukemia

KW - Alternative splice variant

KW - Loss of heterozygosity

KW - Naf1/ABIN-1/TNIP1

KW - Nuclear factor κB

UR - http://www.scopus.com/inward/record.url?scp=39049178223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39049178223&partnerID=8YFLogxK

M3 - Article

C2 - 17016622

AN - SCOPUS:39049178223

VL - 18

SP - 917

EP - 923

JO - International Journal of Molecular Medicine

JF - International Journal of Molecular Medicine

SN - 1107-3756

IS - 5

ER -